A phase 1 trial of zilovertamab in patients with chronic lymphocytic leukemia (CLL) found this mAb was well tolerated and effective in inhibiting ROR1-signaling and cancer-stemness gene expression in leukemia cells of treated patients [13]. This evidence concerns the gene ROR1 and cancer.